Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7598343 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(4 years from now) | |
US7582727 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(4 years from now) | |
US7582727 (Pediatric) | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(4 years from now) | |
US7598343 (Pediatric) | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(4 years from now) |
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11903993 | MAIA PHARMS INC | Ready-to-use bivalirudin compositions |
May, 2039
(15 years from now) | |
US11918622 | MAIA PHARMS INC | Ready-to-use bivalirudin compositions |
May, 2039
(15 years from now) |
Market Authorisation Date: 25 July, 2019
Treatment: Use as an anticoagulant in patients undergoing percutaneous coronary intervention (pci)
Dosage: SOLUTION;INTRAVENOUS